keyword
MENU ▼
Read by QxMD icon Read
search

DLBCL

keyword
https://www.readbyqxmd.com/read/28918104/peripheral-blood-lymphocyte-to-monocyte-ratio-at-relapse-predicts-outcome-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-rituximab-era
#1
Daisuke Katoh, Yotaro Ochi, Tomohiro Yabushita, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Shuichiro Kaji, Yukihiro Imai, Takayuki Ishikawa
BACKGROUND: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have a poor prognosis, even in the rituximab era. Several studies have reported the clinical importance of the peripheral blood lymphocyte-to-monocyte ratio (LMR) in various malignancies, including lymphoma. However, the prognostic value of the LMR in relapsed/refractory DLBCL has not been well evaluated. The purpose of the present study was to investigate whether the LMR at relapse can predict clinical outcomes for relapsed/refractory DLBCL patients treated with rituximab...
August 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28912427/dna-methylation-profiling-reveals-common-signatures-of-tumorigenesis-and-defines-epigenetic-prognostic-subtypes-of-canine-diffuse-large-b-cell-lymphoma
#2
Serena Ferraresso, Arianna Aricò, Tiziana Sanavia, Silvia Da Ros, Massimo Milan, Luciano Cascione, Stefano Comazzi, Valeria Martini, Mery Giantin, Barbara Di Camillo, Sandro Mazzariol, Diana Giannuzzi, Laura Marconato, Luca Aresu
Epigenetic deregulation is a hallmark of cancer characterized by frequent acquisition of new DNA methylation in CpG islands. To gain insight into the methylation changes of canine DLBCL, we investigated the DNA methylome in primary DLBCLs in comparison with control lymph nodes by genome-wide CpG microarray. We identified 1,194 target loci showing different methylation levels in tumors compared with controls. The hypermethylated CpG loci included promoter, 5'-UTRs, upstream and exonic regions. Interestingly, targets of polycomb repressive complex in stem cells were mostly affected suggesting that DLBCL shares a stem cell-like epigenetic pattern...
September 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28912291/high-risk-dlbcl-interim-pet-not-yet
#3
Mark Hertzberg
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28910872/-pathologic-subtyping-of-primary-lymphoma-of-breast-and-prognostic-analysis
#4
Z J Zhou, J L Xie, P Wei, X G Zhou
Objective: To investigate the pathological types and prognostic factors of primary lymphoma of breast (PLB). Methods: The clinical pathological data of 115 cases of PLB during October 2006 to October 2016 were retrospectively analyzed, and the basic clinical and pathological data, pathology types and the immunohistochemical slides by EliVision two-step method for staining were summarized. Results: Almost all the patients were women (113/115), and the median age was 52 years old (range: 27 to 81 years old). The main symptom was painless progressive mass in breast...
September 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28910870/-primary-mediastinal-large-b-cell-lymphoma-a-clinicopathologic-study-of-27-cases
#5
Q Y Shi, X Feng, H Chen, H H Ma, Z F Lu, Q L Shi, X J Zhou, Q Shen
Objective: To study the clinicopathologic characteristics and diagnostic criteria of primary mediastinal B-cell lymphoma (PMBL), and to distinguish PMBL from classic Hodgkin lymphoma(CHL) and systemic diffuse large B-cell lymphoma(DLBCL). Methods: The clinical features, histologic findings, results of immunohistochemical study and prgnosis in 27 PMBL cases were analyzed, with review of literature. Results: The age of patients ranged from 19 to 82 years (median age 34 years). All cases were located in the mediastinum and frequently accompanied by superior vein cava syndrome...
September 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28902958/nonregenerative-immune-mediated-anemia-associated-with-a-diffuse-large-b-cell-lymphoma-in-a-captive-jaguar-panthera-onca
#6
Monika A Keresztes, Manfred Henrich, Penelope Baloi, Sascha Gerst, Jens-Christian Rudnick, Judith Langenstein, Andreas Moritz, Natali Bauer
An 18-year-old male castrated jaguar (Panthera onca) was presented with anorexia and continuous bleeding from the oral cavity after a history of fighting with the partner animal. Clinical evaluation revealed ulcerating lesions on the gingiva and hard palate and a hematoma on the tongue. Computed tomography of the head and endoscopic examination of the esophagus and stomach were unremarkable. Hematology and clinical chemistry revealed severe nonregenerative anemia, mild thrombocytopenia, and moderate azotemia...
September 13, 2017: Veterinary Clinical Pathology
https://www.readbyqxmd.com/read/28895406/identification-of-potential-key-genes-associated-with-diffuse-large-b-cell-lymphoma-based-on-microarray-gene-expression-profiling
#7
X Luo, F Shi, H Qiu, Y Tong, X Gao
The study aimed to screen potential key genes, and their targeted miRNAs and transcription factors (TFs) that were related to diffuse large B-cell lymphoma (DLBCL), and explore potential therapeutic targets for the progression of DLBCL. Dataset GSE56315 extracted from human tonsils was downloaded from Gene Expression Omnibus. Limma package was used to identify differential expression genes (DEG) between DLBCL and normal human tonsils samples, and the function and pathway enrichment analyses were performed. Then, functional interaction (FI) networks analyses of DEGs were implemented, and modules were extracted...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28893618/lenalidomide-modulates-gene-expression-in-human-abc-dlbcl-cells-by-regulating-ikaros-interaction-with-an-intronic-control-region-of-spib
#8
Lauren A Solomon, Carolina R Batista, Rodney P DeKoter
Activated B cell diffuse large B cell lymphoma (ABC-DLBCL) has poor prognosis compared to other DLBCL types, and therefore represents a top priority for developing novel therapies. Lenalidomide, an immunomodulatory drug in trials for treatment of ABC-DLBCL, targets the transcription factor IKAROS for degradation by the Cereblon E3 ubiquitin ligase complex. In this study, we determined whether the gene encoding the transcription factor SPI-B is a target of IKAROS. Using cultured ABC-DLBCL cell lines, we found that high levels of SPI-B expression conferred resistance to lenalidomide...
September 8, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/28884033/high-grade-b-cell-neoplasm-with-surface-light-chain-restriction-and-tdt-coexpression-evolved-in-a-myc-rearranged-diffuse-large-b-cell-lymphoma-a-dilemma-in-classification
#9
Dina Sameh Soliman, Ahmad Al-Sabbagh, Feryal Ibrahim, Ruba Y Taha, Zafar Nawaz, Sarah Elkourashy, Abdulrazzaq Haider, Susanna Akiki, Mohamed Yassin
According to World Health Organization (WHO) classification (2008), B-cell neoplasms are classified into precursor B-cell or a mature B-cell phenotype and this classification was also kept in the latest WHO revision (2016). We are reporting a male patient in his fifties, with tonsillar swelling diagnosed as diffuse large B-cell lymphoma (DLBCL), germinal center. He received 6 cycles of RCHOP and showed complete metabolic response. Two months later, he presented with severe CNS symptoms. Flow cytometry on bone marrow (BM) showed infiltration by CD10-positive Kappa-restricted B-cells with loss of CD20 and CD19, and downregulation of CD79b...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/28883511/cytotoxic-response-against-epstein-barr-virus-coexists-with-diffuse-large-b-cell-lymphoma-tolerogenic-microenvironment-clinical-features-and-survival-impact
#10
Melina Cohen, Aldana G Vistarop, Fuad Huaman, Marina Narbaitz, Fernanda Metrebian, Elena De Matteo, María V Preciado, Paola A Chabay
Epstein-Barr Virus (EBV) is present in neoplastic cells of 15% of Asian and Latin-American diffuse large B-cell lymphoma (DLBCL) patients. Even though a tolerogenic microenvironment was recently described in DLBCL, little is known concerning immunomodulatory features induced by EBV. As suggested in Hodgkin lymphoma, EBV-specific cytotoxic T-cells are increased but showing immune exhaustion features. Hence, host immunity suppression may play a critical role in tumor progression. This study aimed to investigate, whether an association between tumor microenvironment features and EBV presence is taking place, and its clinical correlate...
September 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28883276/acute-exacerbation-of-organizing-pneumonia-leading-to-sudden-death-in-a-patient-with-sarcoidosis-lymphoma-syndrome
#11
Kazuhide Iizuka, Jun Ando, Azuchi Masuda, Tomonori Ochiai, Ran Tomomasa, Hajime Yasuda, Tomoiku Takaku, Yasunori Ota, Takashi Yao, Akihiko Gotoh, Norio Komatsu
The subject was an 83-year-old female; she had a history of Propionibacterium acnes-related sarcoidosis at the age of 79 years. At diagnosis, she was treated with clarithromycin and achieved remission. Four years later, during a routine physical check-up, she presented with pulmonary opacities and swelling of multiple lymph nodes. A definitive diagnosis of lymphoma could not be made by inguinal lymph node biopsy. The patient's general condition was good, and we observed her clinical course. Oh the 56th day of her illness, she died suddenly...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28881739/a-phase-i-trial-of-azacitidine-and-nanoparticle-albumin-bound-paclitaxel-in-patients-with-advanced-or-metastatic-solid-tumors
#12
Adam L Cohen, Abhijit Ray, Matthew Van Brocklin, David M Burnett, Randy C Bowen, Donna L Dyess, Thomas W Butler, Theresa Dumlao, Hung T Khong
BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety and maximum tolerated dose and to assess any clinical activity of the combination of azacytidine and weekly nanoparticle-albumin-bound (nab®) paclitaxel...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28880986/association-of-disease-location-and-treatment-with-survival-in-diffuse-large-b-cell-lymphoma-of-the-eye-and-ocular-adnexal-region
#13
Aseef H Ahmed, C Stephen Foster, Carol L Shields
Importance: Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, and the utility of surgery and radiation therapy remains unresolved. Objective: To explore the clinical characteristics and determine factors associated with overall survival in primary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)-uveal DLBCL. Design, Setting, and Participants: This retrospective analysis included 396 patients with ophthalmic DLBCL from January 1, 1973, through December 31, 2014, using the Surveillance, Epidemiology, and End Results database...
September 7, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28879630/polymorphism-in-ikzf1-gene-affects-clinical-outcome-in-diffuse-large-b-cell-lymphoma
#14
Marta Bielska, Maciej Borowiec, Dorota Jesionek-Kupnicka, Marcin Braun, Marcin Bojo, Agata Pastorczak, Ewa Kalinka-Warzocha, Monika Prochorec-Sobieszek, Tadeusz Robak, Krzysztof Warzocha, Wojciech Młynarski, Ewa Lech-Marańda
IKZF1 encodes a transcription factor involved in B-cell maturation and differentiation. We genotyped 218 diffuse large B-cell lymphoma (DLBCL) patients and 715 unrelated controls using a TaqMan allelic discrimination assay. No statistical difference was observed in the genotype distribution of the IKZF1 rs4132601 polymorphism between DLBCL patients and controls. However, the 2-year PFS rate of patients with the IKZF1 TT genotype was 54.3% compared to 68.6% in those with the IKZF1 G+ genotypes. Moreover, the IKZF1 rs4132601 polymorphism retained its independent prognostic impact on PFS...
September 6, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28877610/the-tumor-suppressive-role-of-inhibin-%C3%AE-a-in-diffuse-large-b-cell-lymphoma
#15
Lei Jiang, Ting Si, Mei Yu, Xinli Zeng, Herbert C Morse, Ying Lu, Guifang Ouyang, Jeff X Zhou
INHBA (inhibin βA), a subunit of a ligand of the transforming growth factor-β superfamily, is known to play diverse roles in various solid tumors. However, its role in hematologic malignancies remains unexplored. Here, we investigated the function of INHBA in diffuse large B-cell lymphoma (DLBCL). Both mRNA and protein levels of INHBA were significantly downregulated in primary DLBCL tissues, irrespective of germinal center B-cell-like (GCB) or non-GCB subtype, compared to those in benign tonsils. The low level of INHBA in patients with de novo DLBCL was correlated with reduced overall and progression-free survival...
September 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28870600/interleukin-10-enhanced-cd8-t-cell-activity-and-reduced-cd8-t-cell-apoptosis-in-patients-with-diffuse-large-b-cell-lymphoma
#16
Huiying Qiu, Xiaoxia Hu, Lei Gao, Li Chen, Jie Chen, Joanna Yuan, Chongmei Huang, Xiaoqian Xu, Jianmin Yang
The pleiotropic cytokine interleukin (IL)-10 is best characterized by its ability to downregulate inflammation and promote peripheral tolerance. On the other hand, IL-10 was also found to maintain the effector response of CD8(+) T cells and promote the expansion of tumor-resident CD8(+) T cells. In diffuse large B cell lymphoma (DLBCL), the role of IL-10 has been characterized in tumor cells but not in CD8(+) T cells. We found that CD8(+) T cells in DLBCL presented robust interferon (IFN)-γ expression early during TCR-activation but could not maintain this response later on, which was characterized by significantly lower CD8(+) T cell degranulation and higher apoptosis...
September 1, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28869931/a-phase-ii-exploratory-study-of-pxd-101-belinostat-followed-by-zevalin-in-patients-with-relapsed-aggressive-high-risk-lymphoma
#17
Soham D Puvvada, José M Guillén-Rodríguez, Xavier I Rivera, Kara Heard, Lora Inclan, Monika Schmelz, Jonathan H Schatz, Daniel O Persky
OBJECTIVE: Aggressive lymphomas (aNHL) including diffuse large B-cell lymphoma (DLBCL) have poor outcomes in relapsed refractory patients. Prior studies have demonstrated that loss of major histocompatibility complex class II (MHCII) expression in DLBCL is associated with poor survival. The objective of this single-arm phase II study was to evaluate if PXD-101 would increase MHCII expression, synergize with Zevalin, and improve clinical outcomes. METHODS: This was a single-center open-label phase II trial (NCT01686165) geared toward heavily pretreated patients with CD20-positive aNHL...
September 5, 2017: Oncology
https://www.readbyqxmd.com/read/28868963/prolonged-hospitalization-primary-refractory-disease-performance-status-and-age-are-prognostic-factors-for-survival-in-patients-with-diffuse-large-b-cell-lymphoma-and-transformed-indolent-lymphoma-undergoing-autologous-stem-cell-transplantation
#18
Bente Arboe, Maja Halgren Olsen, Anne Katrine Duun-Henriksen, Jette Sønderskov Gørløv, Kristina Fruerlund Nielsen, Rasmus Heje Thomsen, Charlotte Madsen, Søren Ramme Nielsen, Susanne Oksbjerg Dalton, Peter de Nully Brown
In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model...
September 4, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28868954/mutational-frequencies-of-cd79b-and-myd88-vary-greatly-between-primary-testicular-dlbcl-and-gastrointestinal-dlbcl
#19
Mareike Frick, Marcus Bettstetter, Simone Bertz, Stephan Schwarz-Furlan, Arndt Hartmann, Thomas Richter, Dido Lenze, Michael Hummel, Martin Dreyling, Georg Lenz, Andreas Gaumann
No abstract text is available yet for this article.
September 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28868942/myc-immunohistochemical-and-cytogenetic-analysis-are-required-for-identification-of-clinically-relevant-aggressive-b-cell-lymphoma-subtypes
#20
Philipp W Raess, Stephen R Moore, Michael J Cascio, Jennifer Dunlap, Guang Fan, Ken Gatter, Susan B Olson, Rita M Braziel
Accurate subclassification of aggressive B cell lymphomas (ABCLs) requires integration of morphologic, immunohistochemical (IHC), and cytogenetic information. Optimal strategies have not been well defined for diagnosis of high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBLwR) and double expressor lymphomas with MYC and BCL2 protein overexpression. One hundred and eighty seven ABCLs were investigated with complete IHC and FISH analysis. Morphologic and IHC analysis was insufficient to identify clinically relevant HGBLwR...
September 3, 2017: Leukemia & Lymphoma
keyword
keyword
98
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"